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ABSTRACT
In 1999 a practical example illustrating the economical
and reliable production of 99mTc from an accelerator was
developed. It included the realistic costs involved in
establishing and operating the accelerator facility and the
distribution of the 99mTc to regions in Florida. However,
the technology was never commercialized.
Recent political and economic developments prompted
this second look at accelerator produced 99mTc. The
practicality of this system in 2007 dollars was established
to account for inflation and current demand. The same
distribution model and production schedule from the
Global ‘99 study were used. Numbers were found using
current rates and costs where possible and indexed
estimations when necessary.
Though several of the costs increased significantly and
the sale price remains at approximately 35¢/mCi, the unit
cost of 99mTc throughput only increased from 12.8¢/mCi
to 25.0¢/mCi or approximately double from 1999 to 2007
thus continuing to be economically viable. This study
provides ground work for creating business development
models at additional locations within the U.S.
*Summer interns from BYU-Idaho, Rexburg, ID. Also
Contributing from BYU-Idaho were Franklin Poulsen, Jonathan
Francis, Jonathan Andrus, and Brian Gee.
**Idaho National Laboratory. Send inquiries to
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I. INTRODUCTION
The initial studies, hereafter referred to as Initial studies,
of an accelerator-based 99mTc supply have assessed
product quality and price based on thermal separation
units (termed ‘goats’ compared to current chemical
separation units termed cows) that are located with the
accelerator.2,3,4 However, the losses and inefficiencies
associated with the distribution of the intermediate 99Mo
product were not fully captured. The Global ‘99 study1
more fully evaluated these effects in a realistic
distribution scenario based on 1996 cost and demand
estimates. The scope of the Global ’99 study included (1)
selecting an updated suitable target market area, (2)
making choices about the throughput and location of the
accelerator, (3) making related choices about the number
and location of regional nuclear pharmacies, as well as the
number of goats to be deployed at each, (4) evaluating
and making changes, where feasible, to the system design
(especially the goats) to afford a more efficient system
and (5) evaluating the overall product cost to determine
the impact of realistic distribution. The present study (1)
utilizes the Global ‘99 methods to appropriately fit current
demand, (2) considers potential system design changes to
the previous Global ’99 method, (3) compares costs and
demand, and (4) demonstrates that the system established
in 1999 is still practical. The majority of the Global ‘99
study has been presented here for background and
informational purposes.
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II. SELECTION OF THE STUDY AREA
The Initial studies at the INL have established that a
single accelerator will be able to supply about 1500-2000
doses of 99mTc per day. The entire U.S. population of 302
million people, a 14% increase over 1996, uses about 14.6
million doses per year or about 46,800 doses per weekday
compared to 38,500 doses per weekday in 1996, a 22%
increase in demand.5 (The demand drops to about 50% on
weekends.) This leads to the claim of the Initial work that
about two dozen accelerators could supply the U.S.
demand. On a per capita basis, about 155 doses are
needed per weekday per million people. Thus, a single
accelerator might be expected to serve a population of
somewhat more than 13 million people.
With a population of nearly 18 million, a 20% increase
from 1996, and a land area of 55,000 square miles,
Florida was chosen for the Global ’99 study since it is
representative of a populous yet dispersed customer base.
With a little over 5% of the U.S. population, Florida
needs about 2870 doses, compared to 2088 doses in 1996,
of 99mTc each weekday (and only about half of this on
weekends). Using Global ‘99 methods, only a portion
would be served without dramatic changes to the process,
therefore for this study it is assumed only the 2088 daily
doses from the Global ’99 study were sold. This
represents about a 73% share of the 2007 market demand
in Florida.
III. POPULATION DEMOGRAPHICS AND CURRENT
99mTc SUPPLY FOR FLORIDA
This study is based on 2005 U.S. Census estimates from
the 2000 census update. Further, the population is
growing at about 1.2% per year in Florida, bringing the
2007 estimated total to 18.3 million. While there are 67
counties and 20 metropolitan statistical areas (MSAs) in
Florida, the 33 least populated counties are not included
in any MSA. The 2007 MSA population totaled 16.8
million, while the entire state totaled 18.3 million. i.e.,
about 8.2% of the population lives in the 33 rural counties
outside of the MSAs.
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A. 'Adjusted' Metropolitan Statistical Areas (MSAs)
One issue the Global ’99 study addressed was the
assignment of the 8.2% of the population living outside
MSAs into logical choices of where they would obtain
diagnostic medical imaging radioisotopes. Case-by-case,
each of the 33 counties was evaluated to determine which
metropolitan areas would likely supply the residents with
unit doses of 99mTc. In this way, 'adjusted MSAs' were
defined that properly capture the entire 18.3 million 2007
population of Florida. The adjusted MSAs are shown in
Figure 1. Then, the region desirable for distribution by a
single accelerator was selected. It was determined that a
population of about 13.3 million could adequately be
served by the single accelerator as will be seen later in
92%
EOB Length of 92%
Irradiation EOB 85%
2 a.m. 23 hr 3%
70%
Milking
Milking
Time of Day
(a.m.)
Time after
EOB
(hr)
Mo-99
in Goat
(Ci)
Tc-99m
in Goat
(Ci)
Tc-99m
Milked
(Ci)
# Doses
6 hours later
Cumulative
Doses
Day or
Goat #
8 6 24.580 19.011 16.159 282.8
1 8 6 23.820 1.484
2 24 19.714 16.568 14.082 246.4
2 2 24 19.085 1.293
5 27 18.492 5.803 4.933 86.3 615.6 1
3 5 27 17.883 0.453
8 30 17.327 4.901 4.166 72.9
4 8 30 16.737 0.383
2 48 13.852 11.558 9.825 171.9
5 2 48 13.363 0.902
5 51 12.948 4.061 3.452 60.4 305.2 2
6 5 51 12.474 0.317
8 54 12.087 3.420 2.907 50.9
7 8 54 11.628 0.267
2 72 9.624 8.031 6.826 119.5
8 2 72 9.244 0.627
5 75 8.957 2.811 2.390 41.8 212.1 3
9 5 75 8.589 0.219
8 78 8.322 2.355 2.002 35.0
10 8 78 7.965 0.184
2 96 6.592 5.501 4.676 81.8
11 2 96 6.297 0.429
5 99 6.102 1.917 1.629 28.5 145.4 4
12 5 99 5.816 0.150
8 102 5.635 1.596 1.356 23.7
13 8 102 5.358 1.125
2 120 4.434 3.701 3.145 55.0
14 2 120 4.205 0.289
5 123 4.075 1.281 1.089 19.1 97.8 5
15 5 123 3.852 0.100
Total Doses
78.6 Ci 1376
Wash Efficiency
Overall Efficiency
Evaporative Loss
Usage Efficiency
Total Tc-99m Milked
Note: An Average Tc-99m dose is 20 mCi at administration.
Table 1. Baseline Melt-Technology Goat Milking Schedule.
at EOB
Tc-99m atMo-99
15.528 Ci26.18 Ci
Time of Day
Separation Efficiency
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this study. Therefore, this study assumes production of
99mTc at full capacity of the accelerator and a 72.8% share
of the Florida market. Growth is possible as processing
and distribution is optimized.
B. Current 99mTc Supply in Florida
Prorated by the above per capita dose rate, the selected
region and percentage of Florida’s population requires
2088 doses per weekday. The supply of 99mTc in the U.S.
is now principally supplied by about 382 regional nuclear
pharmacies nationwide. This represents a 255% increase
over the 150 regional nuclear pharmacies in 1999. Thirty-
seven of these pharmacies are located in Florida
compared to 11 in 1999. The regional areas of Miami and
Tampa have head-to-head competition. If we lump
competing centers together, this means that Florida is
effectively served from 7 regional centers today. It was
assumed that the current distribution of 99mTc doses is
fully served by these centers alone. For any subsequent
business development studies, it may be noted that each
‘adjusted MSA’ has an independent nuclear pharmacy.
Over the state, the average delivery distance by car of a
unit dose of 99mTc to a hospital or clinic from a nuclear
pharmacy is only about 17 miles.
IV. OPTIONS TO ACHIEVE DESIRED
ACCELERATOR 99Mo THROUGHPUT
To understand the modifications to the single accelerator
and collocated separation system required to meet a 2088
dose/day demand in the Florida region with the given
market share, it begins with the melt-technology6 baseline
system from the initial cost estimate study.2 A spreadsheet
analysis of the overall irradiation and separation
performance is found in Table 1. Using a 14.4g 100Mo
target and a 14 kW, 40 MeV electron accelerator, a total
of 26.2 Ci of 99Mo is induced in 23 hours at the end of
bombardment (EOB) at 2 a.m. each day. The target is to
be dissolved in nitric acid, loaded into a single goat and
available for the first separation six hours later, at 8 a.m.
A herd of five goats performed all of the separations,
three times a day. The complete milking schedule is
shown for the 15 milkings of one goat. For each milking,
two lines appear, showing the same time of day. The first
line shows conditions just prior to milking, and the second
just after. Since a new goat is loaded each day on the
same schedule, the 5 day milking schedule is, in fact,
equivalent to the five goats in the herd on any given day if
the word 'Day' is switched to 'Goat Number'. This
schedule is based on the melt-technology goats, which
were conservatively assumed to have an overall efficiency
of 85% and MoO3 evaporative losses of 3% per milking
cycle. The initial cost estimate study baseline system
would produce a total of 1376 doses at time of sale each
weekday. The sensitivity of the throughput to the percent
evaporative loss per cycle is shown in Figure 2 of the
Global ‘99 study, where each percent increase in
evaporative loss per cycle equates to a 5% increase in
required throughput.
The authors of the Global ’99 study had two objectives in
the modifying of the system. First, the required 1996
demand of 2088 doses had to be met. Second, the
problems caused by separating smaller samples coming
from the use of a much larger number of goats (placed at
the selected regional pharmacy sites) had to be
anticipated. The central difficulty with melt-technology is
the evaporative loss, which does not scale down with
smaller separation size—the loss is fixed by the goat
condenser dimensions and is unrelated to the charge of
99Mo loaded in the goat. With this in mind, the authors
decided to explore the viability of the alternative powder-
technology7 goats. This technology does not suffer from
evaporative losses and has had limited demonstration of
improved separation efficiency. However, the technology
does require a more time consuming
redissolve/reprecipitate step between milkings in their
operation.
A. Powder Technology for 99mTc Separation in Goats
The Global ’99 baseline powder-technology separation
schedule is shown in Table 2. The same initial loading of
99Mo is made available as in the melt-technology case.
With the elimination of evaporative losses and slightly
higher efficiencies of separation and washout, the doses at
time of sale were improved to 1720, still short of the 2088
goal. The sensitivity of the throughput to the thermal
separation or washout efficiency is shown in Figure 3 of
the Global ‘99 study, where each percent increase in
efficiency equates to about a 1% decrease in required
throughput. The sensitivity to washout efficiency is about
half again as large as the sensitivity to thermal separation
efficiency. For the goal quantity to be met, the EOB 99Mo
must be increased to 31.8 Ci, up 21.4% from 26.2 Ci.
Further efficiency improvements cannot meet this need.
Rather, from the original baseline study it was determined
that a target almost exactly double in size (28.9 g) under
the same accelerator beam would meet this required
throughput. Additional options for increasing the 99Mo
production are described in Section IV.D.
B. Location of the Accelerator and the Regional
Pharmacies
Increasing the 99Mo throughput by doubling target size
only partly meets the objective since it was still based on
the initial cost estimate study’s2 set of five centralized
goats for the separation. From the Global ’99
demographics, the authors concluded that Florida might
be served by as few as seven regional nuclear pharmacies,
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compared to effectively 11 pharmacies then. This study
shows that 2007 Florida demographics could also be
served by seven regional pharmacies. The proposed 2007
supply network is detailed in Table 3 and shown in Figure
2. The heavy infrastructure of air travel in the Orlando
area can be exploited by placing the accelerator near the
Orlando airport. A nuclear pharmacy is also located in
Orlando, although it does not need to be near the airport.
Tampa is another pharmacy location; it can easily be
served from the accelerator by ground transportation,
being only about 90 miles away. The other five
pharmacies are at West Palm Beach, Jacksonville, Miami,
Pensacola, and Ft. Myers, which are all served by air. If
commercial air is not prohibitive, commercial passenger
jet service is available from Orlando with departures
scheduled between 7 and 8 p.m. daily to every one of
these cities. In each case the flying time is about one hour,
so the 99Mo deliveries would arrive at the pharmacies at
98%
EOB Length of 95%
Irradiation EOB 93%
2 a.m. 23 hr 0%
70%
Milking
Milking
Time of Day
(a.m.)
Time after
EOB
(hr)
Mo-99
in Goat
(Ci)
Tc-99m
in Goat
(Ci)
Tc-99m
Milked
(Ci)
# Doses
6 hours later
Cumulative
Doses
Day or
Goat #
8 6 24.580 19.011 17.699 309.7
1 8 6 24.580 0.380
2 24 20.343 16.952 15.782 276.2
2 2 24 20.343 0.339
5 27 19.711 5.451 5.075 88.8 674.7 1
3 5 27 19.711 0.109
8 30 19.100 5.126 4.773 83.5
4 8 30 19.100 0.103
2 48 15.807 13.148 12.241 214.2
5 2 48 15.807 0.263
5 51 15.317 4.235 3.943 69.0 366.7 2
6 5 51 15.317 0.085
8 54 14.841 3.983 3.709 64.9
7 8 54 14.841 0.080
2 72 12.283 10.217 9.512 166.5
8 2 72 12.283 0.204
5 75 11.902 3.291 3.064 53.6 285.0 3
9 5 75 11.902 0.066
8 78 11.532 3.095 2.882 50.4
10 8 78 11.532 0.062
2 96 9.544 7.939 7.391 129.3
11 2 96 9.544 0.159
5 99 9.248 2.557 2.381 41.7 221.4 4
12 5 99 9.248 0.051
8 102 8.961 2.405 2.239 39.2
13 8 102 8.961 0.048
2 120 7.416 6.169 5.743 100.5
14 2 120 7.416 0.123
5 123 7.186 1.987 1.850 32.4 172.1 5
15 5 123 7.186 0.040
Total Doses
98.3 Ci 1720
Total Tc-99m Milked
Note: An Average Tc-99m dose is 20 mCi at administration.
Table 2. Baseline Powder-Technology Goat Milking Schedule.
at EOB
Tc-99m atMo-99
15.528 Ci26.18 Ci
Time of Day
Separation Efficiency
Wash Efficiency
Overall Efficiency
Evaporative Loss
Usage Efficiency
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10-11 p.m., allowing an hour or two to accomplish pickup
and ground travel to the pharmacy. The necessary number
of doses dispensed by each pharmacy is listed in Figure 2,
along with the proposed supply lines to the adjacent
MSAs. Note that the average distance of delivery of a
dose of 99mTc by car from this smaller set of seven
pharmacies rises to about 37 miles, which is felt to be a
manageable increase from the approximate 17 mile
average.
C. Shipment of 99Mo Target Material to the Regional
Pharmacies
Deploying the 99mTc supply with seven regional
pharmacies implies that a herd of goats will reside at each
pharmacy. With the same five-day milking schedule, this
means that five goats will be active in each pharmacy, for
a total of 35 goats altogether. Two options for supplying
99Mo to them were examined by the Global ‘99 study.
First, the accelerator targets could be adjusted to the
appropriate size to meet the individual pharmacy needs.
At EOB the target is simply disassembled and packed for
shipment as activated Mo metal discs. To meet the first 7
p.m. flight, the EOB would need to be scheduled for no
later than 6 p.m.
The second option was to dissolve and oxidize the target
in nitric acid, evaporate it to dryness, and redissolve the
precipitate MoO3 in NH4OH. This was previously studied
in some detail with supporting experiments to
demonstrate the proposed kinetics.8 The unit operations
are summarized in Table 4. The key result was that
centralized preparation of aliquots will require only 3
hours. This has the especially nice advantage that 99Mo
Table 3. Accelerator-Based Tc-99m Distribution for Florida with 7 Regional Nuclear Pharmacies.
(Boldface entries are regional nuclear pharmacy locations.)
Adjusted MSA Grouping
2007
Population
MSA
Doses/Day*
Served by
Pharmacy
Distance
(miles)
Pharmacy
Doses/Day*
72.8% of
Market
Orlando, FL MSA 2,018,599 314 1 10 596 434
Lakeland-Winter Haven 670,807 105 1 47
Melbourne-Titusville-Palm Bay, FL MSA 543,444 85 1 54
Deltona-Daytona Beach-Ormond Beach, FL MSA 589,514 92 1 71
West Palm Beach-Boca Raton, FL MSA 1,295,672 202 2 10 574 418
Ft. Lauderdale, FL MSA 1,818,026 283 2 43
Fort Pierce-Port St. Lucie, FL MSA 572,189 89 2 54
Tampa-St. Petersburg-Clearwater, FL MSA 2,743,594 427 3 71 540 393
Sarasota-Bradenton-Venice, FL MSA 723,551 113 3 53
Jacksonville, FL MSA 1,299,726 202 4 10 444 324
Gainesville, FL MSA 513,610 80 4 62
Ocala, FL MSA 571,730 89 4 95
Tallahassee, FL MSA 464,060 73 4 163
Miami, FL MSA 2,519,054 392 5 10 392 285
Pensacola, FL MSA 447,468 70 7 10 142 103
Panama City, FL MSA 203,674 32 7 103
Fort Walton Beach, FL MSA 256,128 40 7 40
Fort Myers - Cape Coral, FL MSA 633,625 99 6 10 179 131
Punta Gorda, FL MSA 192,980 30 6 34
Naples, FL MSA 319,999 50 6 35
Total Florida 18,397,450 2867 37 (avg.) 2867 2088
*Basis of Estimate:
14,600,000 Doses per Year for the 302,000,000 U.S. Population 52 x 6 =312 'Full' production days per year (Sat-Sun fall to 50%)
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dispensed and shipped as small aliquots greatly facilitates
alteration of the amount delivered to each pharmacy. This
flexibility even allows the possibility of 'load following'
the actual bookings of next day prescriptions at the
pharmacies. To meet the first 7 p.m. flight, the EOB
would need to be scheduled for no later than 3 p.m. The
sensitivity of the required throughput to the time delay
from EOB until first separation (at 2 a.m.) is shown in
Figure 5 of the Global ‘99 study. Each additional hour's
delay causes a fairly modest 1% increase in required
system throughput, so the distributed system is not overly
sensitive to the time required for target processing before
distribution.
D. Adjusting the Accelerator Option
The Global ‘99 study allowed only the options listed
above for increasing throughput of the 99Mo. However,
adjusting the power level of the accelerator would also
allow the adjustment of the supply. A 19.5 kW, 40 MeV
Unit Operation
Design
Cycle
Time
(min)
Best
Possible
Cycle Time
(min)
1. Transfer targets from accelerator 15 10
2. Dissolve pellets in 7 M HNO3 75 70
3. Evaporate nitritc acid to dryness 75 60
4. Add 7 N NH4OH to dissolve residue 10 10
5. Dispense aliquots for shipping 20 15
Total Cycle Time 195 165
(3hr 15 min)
Table 4. Unit Operations to Prepare 99Mo Aliquots for Distribution
Following Accelerator EOB.
(2hr 45 min)
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electron accelerator would be able to provide the full
demand of doses/day for Florida. The second option is to
operate two smaller regional accelerators of about 10 kW
power level each. Alternatively, increasing the
accelerator size to about a 17 kW power level would meet
the 2088 doses per day demand used in the Global ‘99
study without changing target size or altering the
distribution and milking schedule. This is based on the
fact that isotope production in an accelerator is directly
proportional to beam current, assuming all other factors
are constant. Thus doubling power and maintaining
electron energy essentially doubles isotope production. It
should be noted that an accelerator can be operated at
lower beam energies without changing the electron
energy, thus allowing a larger accelerator to vary
production up to its design limits in beam power.9
E. Summary of 99Mo Throughput Options
The 99Mo throughput options from the Global ’99 study
are summarized in Table 5. The prior melt-technology
baseline uses only 5 goats and ends bombardment at 2
a.m. to meet the first milking at 8 a.m. It produces 1376
doses. Next, the inherent efficiency of the corresponding
powder-technology baseline improves throughput to yield
1720 doses. The third option doubles the target size to
yield the required 2088 doses for Florida—but the
distribution of 99mTc doses to the entire state is impractical
from a single, centralized pharmacy. Next, the options for
distribution of solid or liquid 99Mo are summarized. For a
7 pharmacy, 35 goat system operating on the schedule to
meet airline flights outlined above, a slight increase is
needed in 99Mo throughput: 32.3 Ci, up only 1.6% from
31.8 Ci in the centralized pharmacy scenario. While the
size of this increase seems surprisingly small, it is a
consequence of the somewhat unfavorable schedule
adopted in the initial cost estimate study’s2 baseline
versus that of the distributed baseline study from Global
‘99. Note that the throughput increase needed to distribute
liquid (NH4)299MoO4 is also very modest: 32.9 Ci, up only
1.9% from 32.3 Ci in the solid distribution case. This
increase seems quite acceptable given the great flexibility
of dispensing and distributing liquid. Finally, an
additional option for a 10 day milking schedule is
developed for both the solid and liquid cases. A 10 day
milking schedule requires 10 goats per pharmacy for a
total of 70 goats in the system. However, it had the
advantage in 1999 of yielding the entire supply for
Florida with no increase in the target size. This is due to
the well-known fact that cows (and in this case, goats) can
be effectively milked for upwards of two weeks before
depleting their 99Mo charge. Finally, as noted in this
update, the accelerator could be changed to meet required
throughput.
While the 70 goat option seems promising, the 35 goat
option with liquid distribution was selected in 1999 as the
preferred system baseline for reasons that are described in
the next section.
V. IMPACT OF DISTRIBUTED DELIVERY ON THE
BASELINE GOAT DESIGN
The initial cost estimate study2 was baselined on a melt-
technology goat, although additional separation
experiments were performed with ammonia and nitric-
acid-generated powders. These powder milking
experiments were performed in both the melt technology
goat, and a much smaller provisional unit that could fit
through the small access hatch of the Radioanalytical
Laboratory (RAL) at the Idaho Nuclear Technology and
Engineering Center (INTEC). Neither the melt nor
provisional powder units were ideally suited to loading
and milking powder: The melt goat had a rather long
MoO3 condenser section which is not entirely necessary
for powder milking, as well as a Pt boat that was too
small to hold the aqueous sample initially loaded into the
unit. On the other hand, the provisional powder unit was
assembled with a small clamshell furnace which led to a
number of compromises in its design, especially for
loading aqueous samples and for 99mTc washout. While a
powder-technology goat has been not specifically
designed, the remarks in Section V were aimed at guiding
a successful design effort for such a goat.
A. Range of Separated Activity
The detailed milking schedule for the 7-pharmacy
network was previously evaluated. It included schedules
for each goat at each pharmacy. (Again, there is an
equivalency between how many days a goat has been
milked and the number of the goat in the herd.) The
baseline powder technology goat for a distributed system
must yield high separation efficiency over a considerable
range of throughput. This range includes both the range of
Case Goats EOB
Mo-99
(Ci)
Doses
per Day
Melt Baseline 5 2 a.m. 26.2 1376
Powder Baseline 5 2 a.m. 26.2 1720
Florida-scale baseline 5 2 a.m. 31.8 2088
Distributed (solid†) 35 6 p.m. 32.3 2088
" 70 6 p.m. 25.1 2088
Distributed (liquid††) 35 3 p.m. 32.9 2088
" 70 3 p.m. 25.7 2088
† Distributed a solid Mo metal target material.
†† Distributed as 2 M (NH 4 ) 2MoO 4 (aq) aliquots.
Table 5. Production Throughput Options for 99Mo Distribution
in Florida.
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activity from beginning to end of life (15 milkings over 5
days), as well as the fourfold range of required activity
between the largest pharmacies (located in Orlando and
West Palm Beach) and the smallest pharmacies (in Ft.
Myers and Pensacola). Table 6 summarizes the overall
range of operation. The distributed baseline is the middle
row with 35 goats. In this case the largest activity a goat
must separate is 4.63 Ci (on the first milking at the largest
pharmacy), and the smallest activity is only 130 mCi (on
the last milking at the smallest pharmacy). Thus, a
powder goat should be able to separate over the range of 5
Ci down to 100 mCi with high efficiency.
The Global ‘99 authors noted that the 99mTc activities
quoted in Table 6 are at time of separation, so the last
milking at a small pharmacy is only yielding three doses
of 99mTc. Such a small milking could be canceled and
offset by a small increase in 99Mo production. In fact, the
5 a.m. and 8 a.m. milkings could be omitted on the last
two days of the campaign, which would raise the smallest
milking up by nearly a factor of two, to 220 mCi/mL. A
complementary alternative would be to extend the
milking schedule at the larger pharmacies to 7-10 days.
With their larger throughput demand, they would not fall
to unacceptable separation levels at the end of life of their
goats. Their increased capacity with 7-10 goats would
considerably reduce the amount of 99Mo sent to the larger
pharmacies, and more than offset the amount of additional
99Mo sent to the smaller pharmacies in order to allow
them to avoid the unacceptable operating conditions of 4-
to 5-day-old goats. From these considerations it was
judged that a goat must be able to separate over the range
of 5 Ci down to 200 mCi with high efficiency.
B. Activity Concentration and Elution Volume
In addition to the throughput range, a goat must be able to
deliver acceptable activity concentration of 99mTc in the
eluate from the washout operation. The industry
expectation is that the activity concentration should be
above about 100 mCi/mL, and that some more
concentrated eluate (upwards of 300 mCi/mL) must be
available for labeling a number of newer, more
demanding radiopharmaceuticals. Table 7 summarizes the
activity concentration range for the various scenarios.
These are derived from the throughput values in Table 6
with the assumption that the baseline goat uses 5 mL of
isotonic saline to wash the 99mTc from a goat. Again the
distributed baseline is found in the middle rows with 35
goats. The Initial studies claimed an activity concentration
always larger than 500 mCi/mL. This was borne out by
the top row, which shows a batch activity concentration
(i.e., mixed mean output from all goats at a pharmacy)
always greater than 790 mCi/mL. The distributed baseline
ranged from 580 mCi/mL for the 2 a.m. milking to 175
mCi/mL for the 8 a.m. milking at the largest pharmacies,
and from 155 mCi/mL for the 2 a.m. milking down to
only 50 mCi/mL for the 8 a.m. milking at the smallest
pharmacy. A similar strategy to the above could
overcome the unacceptably low activity concentration of
the smallest pharmacy: That is, some milkings could be
omitted from the schedule for goats in the smallest
Table 6. Scaling Requirements on Goats for 99mTc Separation Throughput.
Goats in
System
Daily
99Mo
(Ci)
First/Last
Separation
(each goat)
Largest
Separation
(mCi)
Smallest
Separation
(mCi)
Ratio of Largest to
Smallest
Separation
5 31.5 9.5 21,450 2,245 9.5
Baseline: 35 32.2 8.9 4,630 130 36
70 25.1 31 3,610 30† 120
† A pharmacy would almost certainly avoid this condition.
Table 7. Scaling Requirements on Goats for 99mTc Activity Concentration.
Goats in
System
Pharmacy
Site
Biggest
Batch
(mCi)
Activity
Concentration
(mCi/mL)
Smallest
Batch
(mCi)
Activity
Concentration
(mCi/mL)
5 - 61,070 2,440 19,800 190
Baseline: 35 Largest 14,570 580 4,370 175
35 Smallest 3,920 155 1170† 50†
70 Largest 14,560 290 4,380 90
70 Smallest 3,910 80 1180† 25†
† A pharmacy would almost certainly avoid this condition.
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pharmacies in order to raise the low end of the activity
concentration range. Alternatively, the required eluate
volume for the goats could be reduced through design and
experiments. Generally, a goal elution volume should be 2
mL, down from the current 5 mL. This would result in
100 mCi/mL activity concentration at the lowest
throughput (200 mCi) for the range derived above. A
further alternative would be to design different size goats
for the larger and smaller pharmacies.
C. Goat Cycle Time
As the Global ‘99 study mentioned, one additional aspect
of goat design should be addressed in future design
work—reducing the time required to cycle the goat
through a milking. Powder goats achieve higher
separation efficiency by exploiting the segregation of
99mTc on the surface of crystals formed when evaporating
the solution in the goat. However, this requires the
dissolution, evaporation and heating steps outlined in
Table 8. It is very important to note that the amount of
99mTc available for separation must be calculated at the
point when the solution finally evaporates: This is near
the end of Step 2 in the Unit Operations of the table.
Following this, an additional 60-70 minutes are required
to complete Steps 3-5 before this 99mTc is actually
available to the radiopharmacist. This implies an 11%
reduction in 99mTc throughput if the one hour wait cannot
be accommodated within the average six hour period
allotted for labeling, dispensing and distribution before
patient administration.
D. Overall Goat Design Recommendations
The overall Global ’99 recommendations for powder goat
design are listed in Table 9. In addition to the
requirements discussed above, a cost target of $l0K is
found in the table. This is necessary to keep the impact on
unit cost very low, and is felt to be feasible given the
simplicity of the goats. This was increased to
approximately $13K for 2007 to account for inflation.
VI. COMPARISON OF COSTS
A rough cost comparison is summarized in Table 10. The
Global ’99 baseline study is found in the first column.
The overall production cost was 12.8¢ per mCi of 99mTc at
time of administration, some six hours following
separation. The present study is found in the second
column labeled, '2007 Distributed Separation.' Both
assume 35 goats are located at 7 regional nuclear
pharmacies. The individual cost components are modified
as follows:
? Facility- Both facilities have the same design
and makeup, but the 2007 cost estimate was
adjusted by the construction inflation rates. This
was used for obvious costs, such as concrete,
gypsum, and steel.10 The remainder, including
design, mechanical equipment, and labor, was
adjusted by average inflation.11
? Equipment- A total of $138K at each of 7
pharmacies was allowed to cover the capital cost
of goats and spares (at $13K each) and
equipment for washout and recycle of goats.
This is adjusted by inflation11 from the Global
‘99 $10K cost in 1996.
? Accelerator- Identical for both cases. The 2007
cost is inflation adjusted estimate.
? Target Inventory- The current price quoted
from the DOE Isotope Program Business Office
at Oak Ridge National Laboratory (ORNL) is
approximately $7500 per gram for calutron-
produced 98.6% enriched 100Mo.12 The authors
of the Global ’99 baseline study used a cost
estimate of $1,000 per gram for 100Mo at 96%
enrichment. This difference alone, added
10¢/mCi to the projected price in 2007. The cost
of enriched 100Mo will vary by method of
enrichment, e.g., centrifuge or calutron, and level
of enrichment, e.g., 90% vs. 98.6%, with the
latter in each case being the more expensive.12
? Total Capital- The total capital required is
increased by $7.3M by the above considerations.
Table 8. Unit Operations to Cycle a Powder Goat.
Unit Operation
Design
Cycle
Time
(min)
Best
Possible
Cycle Time
(min)
1. Add 7 N NH4OH to dissolve residue 20 10
2. Evaporate to dryness without boiling 60 20
3. Heat goat up to milking temperature 30 20
4. Milk 99mTc at temperature 20 20
5. Cool goat, extract 99mTc and rinse 20 20
Total Cycle Time 150 90
(2 hr 30 min) (1 hr 30 min)
Table 9. Recommended Goat Design Features.
• Loads up to 250 mL aliquot volume for separation
• Unloads boat contents for return to accelerator
• Achieves near-0% sample mass loss per milking cycle
• Achieves high efficiencies: 98% separation, 95% washout
• Separates from 5 Ci (largest) to 200 mCi (smallest) 99mTc
• Total cycle time of 2 hr or less
• Cost $5K-10K per goat, including controls and shielding
• Achieves 100mCi/mL activity concentration for the smallest
separations (2 mL elution volume)
• Cycle time from precipitation through elute recovery of 1 hr or
less
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? Cost of Capital- Both cases are based on 20%
cost of capital per year.
? Technician Salaries- Based on $53K base salary
for technicians plus 50% fringe. The initial
study’s2 baseline was reduced by one staff
member for the distributed case to reflect not
needing to separate 99mTc at the accelerator.
However, one staff member was added at each
regional pharmacy to handle goat loading and
target material return as well as receipt and
shipping of target material.
? Utilities- Identical demand for both cases. This
cost is dominated by the electric power
requirement of the accelerator. Adjusted by the
electricity rate increase in Florida from 1996 to
2007 according to Energy Information Agency.
? Maintenance/Repair- about $l3K per site per
year is added to accommodate goat upkeep
adjusted for inflation11 from the Global ’99
estimate of $10K.
? Supplies/Services- This reflects a seven fold
increase in cost of 100Mo replenishment, as well
as an inflation indexed increase in cost of
miscellaneous supplies and services and
Klystron refurbishment.
? Shipping- This reflects daily air shipments of
99Mo aliquots, plus local ground transportation in
the average amount of about $115 per day per
site. This should allow enough contingency
within the estimate to handle special shipments
and airport cancellations. It is assumed that labor
associated with ground transport is covered by
the additional technician salary at each site
identified above. Both estimates are far above
standard freight and would be a fairly
conservative estimate.13
? Total Variable- The total yearly variable cost is
increased by about $2.3M by the considerations
above.
The overall production cost in the 2007 distributed case is
approximately doubled to 25.0¢ per mCi of 99mTc at time
of administration, six hours following separation. This
increase compares favorably to the market price of ~35¢
per mCi today. Thus, the overall conclusion is that the
cost impact of a fully distributed production system in
2007 remains below market pricing of the product.
VII. DISCUSSION
The prior studies developed a cost estimate that included
all the costs involved in establishing the facility with all
the equipment. In order to update that cost estimate for
the purposes of this study, several methods and
Table 10. Updated Distributed vs. Previous Distributed 99mTc Cost Study Comparison. (Costs in Thousands)
Capital
Facility 1400 sq. ft. 910$ 1400 sq. ft. 1,258$
Central 345 Central 478
Local 700 Local $969
2,000 2,768
900 g 900 900 g 6,633
4,855$ 12,106$
Variable
971$ 2,421$
5 Central 300 403
7 Local 420 564
Utilities 65 up 9.6% 71
100 138
300 797
Shipping $700/day 218 $800/day 250
2,374$ 4,645$
18,613 Ci 18,613 Ci
12.8 ¢/mCi 25.0 ¢/mCi
Target Inventory
Accelerator (40 MeV, 14 kW)
Laboratory Equipment
2007 Distributed Separation1996 Distributed Separation
add $13K per site
Unit Cost of 99mTc
Technician Salaries
Total Variable
Yearly Output
add $10K per site
Cost of Capital
Total Capital
Maintainance/Repair
Supplies/Services
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assumptions were made. The Associated General
Contractors of America gave a history of inflation of
construction costs. This was used to determine the cost
increase for concrete, steel, and gypsum from the Global
‘99 cost estimate. All other costs were increased by
inflation of 3% per year. This is approximately the
average inflation from 1996 to 2007 and includes a small
contingency.11 Utilities were updated using historical
average cost of electricity from 7.99 to 8.76¢ per
kilowatt-hour in Florida. Salaries and Equipment were
adjusted by 3% inflation. Doubling target size at these
costs seems to be the least effective way of achieving the
required throughput. The cost of the entire system is
heavily based upon the cost of the target material.
If commercial air freight is prohibitive for radioactive
materials an alternative method of shipping needs to be
available. A second method to estimate shipping of the
99Mo aliquots via a fleet of small company cars was also
evaluated. It assumed that the cars had an average of 30
miles to the gallon, and a gallon of gasoline cost $3.03.14
Also it afforded reasonable delivery times for the
pharmacies, because the delivery time would not greatly
impact the first milking due to the 1% loss per additional
hour stated in the Global ‘99 study. Drivers were to be
paid $12.50 an hour and the car payments and insurance
were estimated at $200 per month for each vehicle. This
still arrives very close to the approximation made above
that shipping would average $115 per site per day.
The accelerator and cost of the maintenance for the
accelerator was evaluated using a sensitivity study. A $4
Million accelerator using the Global ‘99 methods for
payment would only increase the above listed cost by
1.3¢/mCi. A recent estimate offered a much more
powerful accelerator with the potential of being in the
range this study indicates, but with additional potential for
growth, was estimated at about $3.25 million. If this unit
were purchased it would increase the cost to produce by
only 0.5 ¢/mCi. Additionally the supplies required to
maintain the accelerator were estimated at about $40,000
each year, changed from $30,000 in the Global ‘99 study.
With $12,000 per year in miscellaneous supplies
compared to the initial study’s2 centralized approximation
of $3,000. The replacement of the Molybdenum-100 was
also taken into account.
The Global ‘99 study looked at a cost estimate for the
whole of Florida, finding that the accelerator model
described would supply the demand for Florida. That
baseline study was adjusted here to provide options for
adjusting the model to any geographic or regional niche
for 99Mo production. It was found in the Global ‘99 study
based on 1996 cost and population figures that such a
system was not only possible, but would be competitive
with the then current subsidized reactor base 99Mo
production. This study was a look at the process used in
the Global ‘99 study, but also addressed 2007 demand in
Florida and 2007 cost estimates. The options suggested
for increasing throughput would not meet the full demand
of Florida. However, it is unlikely that 100% of the
market will utilize the goat powder method over the
existing cow technology. Therefore, this study included a
smaller portion of the Florida market, matched the Global
‘99 study in 99mTc output, and used current costs for
production. Our results show electron accelerator
production of 99Mo combined with a distributed regional
pharmacy system could be economically feasible in
Florida today, and reinforce the findings of the earlier
studies that total US demand could be supplied by about
20 such production/distribution systems nationwide.
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